The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes

Seelig E., Howlett J., Porter L., Truman L., Heywood J., Kennet J., Arbon EL., Anselmiova K., Walker NM., Atkar R., Pekalski ML., Rytina E., Evans M., Wicker LS., Todd JA., Mander AP., Bond S., Waldron-Lynch F.

DOI

10.1172/jci.insight.99306

Type

Journal article

Journal

JCI Insight

Publisher

American Society for Clinical Investigation

Publication Date

04/10/2018

Volume

3

Permalink Original publication